Literature DB >> 6283120

Two large virion envelope glycoproteins mediate Epstein-Barr virus binding to receptor-positive cells.

A Wells, N Koide, G Klein.   

Abstract

The four major Epstein-Barr virion envelope components were separated by column chromatography and reconstituted into artificial liposomes. These liposomes were tested for their ability to bind selectively to Epstein-Barr virus receptor-positive cells. Only when the two high-molecular-weight glycoproteins, VE1 and VE2, were present together was a stable binding complex formed. The addition of the other virion envelope components did not increase the levels of binding. This binding was inhibited by unlabeled viable virions and by neutralizing antisera, which recognized the two components. Adsorption of viable virus was also eliminated by the antisera. The enzyme susceptibility pattern of the cell-liposome interaction is similar to that of the virus-cell interaction, thus confirming the specificity of the binding site. A model for Epstein-Barr virus binding in which VE1 and VE2 coordinately recognize the same binding site is presented.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6283120      PMCID: PMC256750     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Preparation of liposomes incorporating membrane components from human lymphoid cells.

Authors:  O Acuto; O Pugliese; M Müller; R Tosi
Journal:  Tissue Antigens       Date:  1979-11

2.  Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus.

Authors:  M Dolyniuk; E Wolff; E Kieff
Journal:  J Virol       Date:  1976-04       Impact factor: 5.103

3.  Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus.

Authors:  M Dolyniuk; R Pritchett; E Kieff
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

4.  Characteristics of Sendai virus receptors in a model membrane.

Authors:  A M Haywood
Journal:  J Mol Biol       Date:  1974-03-15       Impact factor: 5.469

5.  Relationship between the EBV-associated membrane antigen on Burkitt lymphoma cells and the viral envelope, demonstrated by immunoferritin labelling.

Authors:  D Silvestre; F M Kourilsky; G Klein; Y Yata; C Neauport-Sautes; J P Levy
Journal:  Int J Cancer       Date:  1971-09-15       Impact factor: 7.396

6.  Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji).

Authors:  M A Epstein; B G Achong; Y M Barr; B Zajac; G Henle; W Henle
Journal:  J Natl Cancer Inst       Date:  1966-10       Impact factor: 13.506

7.  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.

Authors:  E Klein; G Klein; J S Nadkarni; J J Nadkarni; H Wigzell; P Clifford
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

8.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

9.  Circulating immune complexes in sera of patients with Burkett's lymphoma and nasopharyngeal carcinoma.

Authors:  R Heimer; G Klein
Journal:  Int J Cancer       Date:  1976-09-15       Impact factor: 7.396

10.  Enzymic iodination. A probe for accessible surface proteins of normal and neoplastic lymphocytes.

Authors:  J J Marchalonis; R E Cone; V Santer
Journal:  Biochem J       Date:  1971-10       Impact factor: 3.857

View more
  14 in total

1.  Localization of Epstein-Barr virus envelope glycoproteins on the inner nuclear membrane of virus-producing cells.

Authors:  M R Torrisi; M Cirone; A Pavan; C Zompetta; G Barile; L Frati; A Faggioni
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

2.  Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells.

Authors:  Y Whang; M Silberklang; A Morgan; S Munshi; A B Lenny; R W Ellis; E Kieff
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

3.  Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.

Authors:  G R Nemerow; C Mold; V K Schwend; V Tollefson; N R Cooper
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

4.  Strain-specific transcription and translation of the BamHI Z area of Epstein-Barr Virus.

Authors:  R Seibl; M Motz; H Wolf
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

5.  Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.

Authors:  J Tanner; Y Whang; J Sample; A Sears; E Kieff
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

6.  A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus.

Authors:  N Miller; L M Hutt-Fletcher
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

Review 7.  Virus receptors: implications for pathogenesis and the design of antiviral agents.

Authors:  L C Norkin
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 8.  Complement-related proteins in pathogenic organisms.

Authors:  Z Fishelson
Journal:  Springer Semin Immunopathol       Date:  1994

9.  Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes.

Authors:  J R North; A J Morgan; J L Thompson; M A Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

10.  Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment.

Authors:  S Keay; B Baldwin
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.